Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice

Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice

On-Demand Webcast

Richard R. Furman, MD
Weill Cornell Medicine
New York, New York


Jennifer R. Brown, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts

John C. Byrd, MD
Ohio State University
Columbus, Ohio

Peter Hillmen, MB, ChB, PhD
University of Leeds
Leeds, United Kingdom

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Kanti Rai, MD
Northwell Health
Hofstra Northwell
School of Medicine
New Hyde Park, New York

Target Audience

Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.


An individualized approach to Chronic Lymphocytic Leukemia (CLL) management is now possible with the targeted therapies and current clinical guidelines to recommend treatment options for the first-line or relapsed/refractory setting based on patient age and genetic biomarkers. However, the diversity of these targeted therapies, with even agents that belong to the same therapeutic class exhibiting differences in their precise mechanisms of action, efficacy, dosing, and adverse effect profiles, also generates new challenges for their appropriate use and optimal placement in therapeutic paradigms. Moreover, the data pool surrounding targeted CLL therapy is continually evolving, featuring expanded indications for first-line therapy or specific relapsed/refractory patient populations; next-generation agents with improved efficacy and safety profiles that are poised to further advance outcomes for patients with CLL.

This on-demand web archive is initiated to address knowledge and practice gaps among physicians, NPs, and PAs pertaining to this rapidly changing treatment landscape for CLL.

  1. Distinguish among the full array of available and emerging targeted therapies for CLL, highlighting both between-class and within-class distinctions in mechanisms of action, efficacy, adverse effect profiles, and indications
  2. Evaluate current and emerging clinical trial data surrounding newer agents and combination strategies that may impact the CLL management paradigm
  3. Address barriers to the optimal implementation of targeted CLL therapies through strategies to improve adherence, persistence, and adverse effect management

Release Date: October 31, 2018

Expiration Date: October 31, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by educational grants from: AstraZeneca, Pharmacyclics, and Verastem Oncology.


Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Imedex designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 credits.

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 2.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.25 contact hours.


This knowledge-based activity (JA0006201-9999-18-219-H01-P) is approved for 2.25 contact hours (0.0225 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Richard R. Furman, MD, Jennifer Brown, MD, John Byrd, MD, Neil Kay, MD and Kanti Rai, MD; Peter Hillmen, MB, CHB PhD and Chris Bolwell, Monalisa Singh, and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Jennifer R. Brown, MD, PhD has received research and/or grant support from Gilead, Lox and Sun, and has served as a consultant for AbbVie, Acerta, BeiGene, Gilead, Janssen, Kite, Loxo, Morphosys, Pfizer, Sunesis, TG Therapuetics, Teva, and Verastem.

John C. Byrd, MD has no financial relationships to disclose.

Richard R. Furman, MD has served as a consultant for AbbVie, Acerta, Genentech, Gilead, Incyte, Janssen, Loxo Oncology, Susesis, TG Therapeutics and Verastem, and has received research and/or grant support from Acerta, TG Therapeutics

Neil E. Kay, MD has received research and/or grant support from Acerta and Pharmacyclics, has served as a consultant for Argios Phrama, Celgene, Cytomx Therapuetics, Gilead, Infinity Pharma, Morph-Sys, and Pharmacyclics, and has received other support from Janssen.

Kanti Rai, MD has no financial relationships to disclose.

Peter Hillmen, MB, ChB, PhD has received research and/or grant support from Gilead, Janssen, Novartis/GSK, Pharmacyclics and Roche, has served as a consultant to AbbVie, Acerta, AstraZeneca, Celgene, Gilead, Janssen, Juno, Novartis/GSK, Pharmacyclics, and Roche

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Monalisa Singh and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME and Imedex require faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the symposium.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.